Regor Therapeutics, a Shangai, China-based clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, closed a $90m Series B financing.
The round was led by Lilly Asia Ventures with participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.
Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
Founded in July of 2018 by Dr. Xiayang Qiu, CEO, Regor is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development.
FinSMEs
19/02/2021